
|Articles|February 16, 2021
Raremark Rebrands as Xperiome
Advertisement
Raremark has announced that it is rebranding as Xperiome. Jeremy Edwards, CEO of Xperiome, commented, “Strategically, we are rebranding because we have two very different audiences, with individual needs that will benefit from equal attention and focus.”
Xperiome will now become the name and corporate identity of the company, while the Raremark brand will solely represent its patient-facing activities dedicated to helping people better understand, talk about and manage rare diseases.
For more information, click
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Beyond Compliance: ProofPilot's Joseph Kim and Lauren Briggs on Making Clinical Trial Training Actually Work
2
Tufts CSDD Analysis Finds AI Clinical Monitoring Agent Can Generate Up to $21 Million in Net Financial Value Per Drug Development Program
3
ACT Brief: Efficacy Ceiling Breakthrough in Autoimmune Disease, Early-Career Retention and Burnout Prevention, and PRV Program Catalyzing Rare Disease Investment
4
Breaking the Efficacy Ceiling in IBD and Beyond
5



